Cargando…

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA

Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance mutations together with efficacy in CNS metastases in patients with non-small-cell lung cancer (NSCLC). Here we descr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuboi, Masahiro, Weder, Walter, Escriu, Carles, Blakely, Collin, He, Jianxing, Dacic, Sanja, Yatabe, Yasushi, Zeng, Lingmin, Walding, Andrew, Chaft, Jamie E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530153/ https://www.ncbi.nlm.nih.gov/pubmed/34278827 http://dx.doi.org/10.2217/fon-2021-0549

Ejemplares similares

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
por: Majem, Margarita, et al.
Publicado: (2022)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

ADAURA update: only the end of the beginning
por: Muthusamy, Bharathi, et al.
Publicado: (2023)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients
por: Li, Feng, et al.
Publicado: (2021)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
por: Long, Yaping, et al.
Publicado: (2021)

ADAURA, a Bridge Connecting Disease Control with Long-term Survival
por: Zhao, Jing, et al.
Publicado: (2021)

Cardiac Safety of Osimertinib: A Review of Data
por: Ewer, Michael S., et al.
Publicado: (2021)

Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network
por: Sallam, Mostafa, et al.
Publicado: (2019)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)
por: Moritani, Konosuke, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions
por: Beugels, J., et al.
Publicado: (2019)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy
por: Pedersini, Rebecca, et al.
Publicado: (2023)

Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade
por: Hennigs, A., et al.
Publicado: (2016)

Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer
por: Chen, Bihong T., et al.
Publicado: (2018)

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience
por: Vriens, Ingeborg J. H., et al.
Publicado: (2020)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities
por: West, Howard (Jack), et al.
Publicado: (2023)

Adjuvant chemoradiotherapy versus chemotherapy or radiotherapy in advanced endometrial cancer: a systematic review and meta-analysis
por: Winarto, Hariyono, et al.
Publicado: (2022)

Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
por: Basi, Ali, et al.
Publicado: (2013)

Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy
por: Song, Wu, et al.
Publicado: (2012)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)

Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?
por: Schaefgen, Benedikt, et al.
Publicado: (2021)

Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer
por: Davey, Matthew G., et al.
Publicado: (2023)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
por: Krajnak, S., et al.
Publicado: (2020)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
por: Iwata, Hiroji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_61p9mt79knor1n8pofaqup6m3a